Three different digital therapeutics, including SilverCloud and Headspace, showed generally similar improvements in depressive and anxiety symptoms after 6 weeks in a randomized clinical trial. (JAMA Network Open)
Can seasonal depression happen in the summer, too? (The Hill)
Among nursing home residents, CYP2D6-metabolized opioids used with CYP2D6-inhibiting antidepressants — like fluoxetine (Prozac) and bupropion (Wellbutrin) — were associated with worsening pain compared with CYP2D6-neutral antidepressants. (Annals of Internal Medicine)
Intravenous ketamine given for 3 consecutive days did not produce a noticeable advantage in reducing depressive symptoms compared with active placebo midazolam, according to a pilot study of people with treatment-resistant depression in Thailand. (BMC Psychiatry)
Johnson & Johnson submitted esketamine nasal spray (Spravato) for FDA approval as a monotherapy for adults with treatment-resistant depression. It’s currently approved in combination with an oral antidepressant for depression with acute suicidal ideation or behavior.
Here’s how one 20th-century French psychiatric hospital spurred a new art movement. (New York Times)
Community-level social vulnerability wasn’t linked with clinical diagnoses of generalized anxiety or major depressive disorder, but was tied with a higher prevalence of schizophrenia spectrum disorder, stimulant use disorder, and opioid use disorder. (JAMA Psychiatry)
Should addiction treatment be fully integrated into healthcare systems, including primary care practices and hospitals? (STAT)
Several mushroom gummy brands marketed as containing legal psychedelic ingredients were found to contain illegal hallucinogens such as psilocybin. (Morbidity and Mortality Weekly Report)
Meanwhile, a study in Nature suggested that psilocybin works by disrupting certain brain networks and temporarily increases brain plasticity.
![author['full_name']](https://clf1.medpagetoday.com/media/images/author/kristenMonaco_188.jpg)
Please enable JavaScript to view the